Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review
出版年份 2011 全文链接
标题
Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review
作者
关键词
-
出版物
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 21, Issue 7, Pages 1109-1127
出版商
Informa Healthcare
发表日期
2011-05-19
DOI
10.1517/13543776.2011.584871
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- 4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors
- (2010) Kevin K.-C. Liu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kα
- (2010) David J. Richard et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- 2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: Optimization of human microsomal stability
- (2010) Jeroen C. Verheijen et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment
- (2010) Carlos García-Echeverría BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors
- (2010) Arie Zask et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer
- (2010) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor
- (2010) Aranapakam M. Venkatesan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design
- (2010) Hengmiao Cheng et al. MedChemComm
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Discovery of 4-Morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as Highly Potent and Selective ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin (mTOR): Optimization of the 6-Aryl Substituent
- (2009) Jeroen C. Verheijen et al. JOURNAL OF MEDICINAL CHEMISTRY
- ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines
- (2009) Arie Zask et al. JOURNAL OF MEDICINAL CHEMISTRY
- Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors
- (2009) Arie Zask et al. JOURNAL OF MEDICINAL CHEMISTRY
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started